H.C. Wainwright initiated coverage on Cibus Global with a new price target
$CBUS
Agricultural Chemicals
Industrials
H.C. Wainwright initiated coverage of Cibus Global with a rating of Buy and set a new price target of $25.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/29/2024 | $25.00 | Buy | Alliance Global Partners |
| 7/19/2024 | $22.00 | Buy | Canaccord Genuity |
| 10/9/2023 | $25.00 | Buy | H.C. Wainwright |
| 7/19/2023 | $30.00 | Buy | Canaccord Genuity |
SAN DIEGO, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS), a leading agricultural technology company specializing in the development and licensing of gene-edited plant traits, today announced its agreement with AgVayā, a strategic growth advisory firm that partners with leading innovators, to develop strategies and solutions for the Indian agriculture market. Together, the companies will define market strategies, build partnerships, and accelerate the introduction of Cibus' gene editing technologies into India's rice seed industry, supporting the development of more resilient and productive rice varieties that are critical to both India's agricultural economy and the global ri
Field testing confirms efficacy of HT2 trait in Canola under real-world conditions HT2 trait will be offered to potential seed licensing partners for introduction into commercial Canola seed products SAN DIEGO, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS) (the "Company"), a leading agricultural technology company developing and licensing advanced gene edited plant traits that enable improved productivity, higher yields, lower input costs, and more sustainable farming, today announced the completion of field testing for its second-generation herbicide tolerance (HT2) edited Canola with positive results. "Our second-generation herbicide tolerance edited canola previously p
SAN DIEGO, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ: CBUS), a leading agricultural technology company developing and licensing advanced plant traits that enable higher yields, lower input costs, and more sustainable farming, today announced the election of Kimberly A. Box to its Board of Directors. "Kim brings to Cibus extensive leadership experience in technology and commercialization that will be invaluable as we sharpen our strategic commercialization efforts," said Mark Finn, Cibus Chairman. "Her understanding of market dynamics and experience in guiding innovation into scalable businesses will strengthen our strategic governance as we continue to drive long-term value c
Alliance Global Partners initiated coverage of Cibus Global with a rating of Buy and set a new price target of $25.00
Canaccord Genuity resumed coverage of Cibus Global with a rating of Buy and set a new price target of $22.00
H.C. Wainwright initiated coverage of Cibus Global with a rating of Buy and set a new price target of $25.00
4 - Cibus, Inc. (0001705843) (Issuer)
3 - Cibus, Inc. (0001705843) (Issuer)
4 - Cibus, Inc. (0001705843) (Issuer)
8-K - Cibus, Inc. (0001705843) (Filer)
8-K - Cibus, Inc. (0001705843) (Filer)
SCHEDULE 13G/A - Cibus, Inc. (0001705843) (Subject)
SAN DIEGO, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies, today announced that the company will report second quarter 2025 financial results on Thursday, August 14, 2025. Cibus' management team will host a conference call and audio webcast at 4:30 p.m. ET on that day to discuss the financial results and other company updates. Title: Cibus, Inc. Second Quarter 2025 Results Conference Call Event Date: Thursday, August 14, 2025Time: 4:30 p.m. ETParticipant Numbers: +1-833-316-2483 (U.S.), +1-785-838-9284 (International)The conference ID "CIBUS" or 24287 will be required for en
Rice business momentum builds with Cibus' first stacked gene edited herbicide tolerance traits, which the Company believes is an industry first; On track for 2027 targeted commercial launch of HT1 and HT3 traits with customer germplasm integration underway across multiple markets Positive regulatory decision for Cibus' Rice traits HT1 and HT3 in Ecuador; the Ministry of Agriculture and Livestock in Ecuador determined that the Company's HT1 and HT3 Rice traits are equivalent to those developed through conventional breeding Disease resistance program advances with positive Sclerotinia data for multiple modes of action against Sclerotinia in Canola; Cibus' time bound and predictable RTDS tech
SAN DIEGO, April 25, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced that the company will report first quarter 2025 financial results on Thursday, May 8, 2025. Cibus' management team will host a conference call and audio webcast at 4:30 p.m. ET on that day to discuss the financial results and other company updates. Title: Cibus, Inc. First Quarter 2025 Results Conference Call Event Date: Thursday, May 8, 2025Time: 4:30 p.m. ETParticipant Numbers: +1-833-316-1983 (U.S.), +1-785-838-9310 (International)The c
SAN DIEGO, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ: CBUS), a leading agricultural technology company developing and licensing advanced plant traits that enable higher yields, lower input costs, and more sustainable farming, today announced the election of Kimberly A. Box to its Board of Directors. "Kim brings to Cibus extensive leadership experience in technology and commercialization that will be invaluable as we sharpen our strategic commercialization efforts," said Mark Finn, Cibus Chairman. "Her understanding of market dynamics and experience in guiding innovation into scalable businesses will strengthen our strategic governance as we continue to drive long-term value c
SAN DIEGO, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS), a leading agricultural technology company specializing in the development and licensing of gene-edited plant traits, today announced that Peter Beetham, Co-Founder, President, and Interim Chief Executive Officer, will participate in a featured panel during UN Climate Week 2025 in New York City. The event, titled "Investing in a Resilient Future: Innovation, Data & Capital for Energy, Food, Water, and Climate Solutions", supported by Syntax Data, will be held on Tuesday, September 23rd at Midtown Loft, New York City, with a livestream available via LinkedIn. Dr. Beetham will join leaders from the United Nations Devel
EMERYVILLE, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Totus Medicines, a company revolutionizing small molecule drug discovery and development using covalent DNA-encoded libraries and AI tools, today announced the appointment of Simon Harnest, MSc, BSc, as Chief Financial Officer. This key addition comes at a pivotal moment for Totus as the company prepares to advance its clinical-stage program following encouraging results from its Phase 1 study of TOS-358, a covalent PI3Kα inhibitor. "The addition of Simon, with over 15 years' experience in private capital markets strategy and IPO processes, comes at the right time for Totus as we advance our clinical-stage and discovery programs," said